- Additional diagnostic tests - We continued the expansion of our microRNA-based diagnostic pipeline with cancer-related indications and indications related to women's health.
- Identified microRNAs that are potential biomarkers for differential diagnosis of the following in lung cancer: primary vs. metastases, non-small cell lung cancer vs. small-cell lung cancer, neuroendocrine tumors vs. non-small cell lung cancer, lung cancer vs. thymoma, and carcinoid vs. other neuroendocrine tumors.
- Identified specific microRNAs that are markers to differentiate between primary liver and brain tumors and metastases to these organs.
- Women's health: Demonstrated correlation between microRNAs in serum and physiological conditions.
Collaborations and Licensing
- Initiated a collaboration with the Henry Ford Health System in Detroit, Michigan, to develop microRNA-based diagnostics and prognostics for brain cancer. Under the collaboration, the parties will conduct a genome-wide molecular analysis of human brain cancer tumors to identify unique microRNA biomarkers that have diagnostic and prognostic potential.
- Signed an agreement with University of California, Irvine School of Medicine, relating to the development and validation of diagnostic tests based on the company's microRNA technology. The tests are designed to differentiate squamous versus non-squamous lung cancer, differentiate mesothelioma from adenocarcinoma, and identify cancers of unknown primary (CUP) origin.
- The U.S. Patent and Trademark Office (USPTO) has issued a Notice of
Allowance for two of the company's patent applications on human
(10/604,726) and viral (10/604,942) microRNAs. The first allowed patent
application (10/604,726) is related to two clustered human hairpins and
their related m
|SOURCE Rosetta Genomics Ltd|
Copyright©2008 PR Newswire.
All rights reserved